Table 3.
Effect of biliopancreatic diversion with duodenal switch on dyslipidemia.
| Study n (number of patients) |
Dislipidemia incidence preoperatively | Resolution of dyslipidemia | Measure of resolution |
|---|---|---|---|
| Crea et al. [24] | A-Hypercholesterolemia 87% | A-Hypercholesterolemia 98% | Hypercholesterolemia/hypertriglyceridemia—Laboratory values within the normal range (not defined) |
| n = 540 | A-Hypertriglyceridemia 53% | A-Hypertriglyceridemia 97% | |
| A-BPD: 287 | B-Hypercholesterolemia 85% | B-Hypercholesterolemia 99% | |
| B-DS: 253 | B-Hypertriglyceridemia 55% | B-Hypertriglyceridemia 99% | |
|
| |||
| Papadia et al. [25] n = 68 |
16% | 100% | Serum cholesterol < 200 mg/dL |
|
| |||
| Vage et al. [35] n = 80 |
48% (on treatment) | 92% | LDL Hyperlipidemia—discontinuation of hypolipidemic agents with LDL < 2.6 mmol/L |
|
| |||
| Dorman et al. [36] n = 329 |
Hyperlipidemia—not defined | ||
| A-BPD/DS: 190 | A-54% | A-81% | |
| B-RYGB 139 | B-44% | B-55% | |
|
| |||
| Prachand et al. [37] n = 350 |
Dyslipidemia—discontinuation of the medications used for treatment with the absence of symptoms | ||
| A-BPD/DS: 198 | A-31% | A-72% | |
| B-RYGB: 152 | B-36% | B-26% | |
|
| |||
| Pata et al. [38] n = 874 |
Hypercholesterolemia 87% Hypertriglyceridemia 53% |
Hypercholesterolemia 98% Hypertriglyceridemia 96% |
Laboratory values within the normal range (cholesterol 120–200 mg/dL, triglycerides < 150 mg/dL) |
BPD: biliopancreatic diversion.
DS: duodenal switch.
Medical: medical management of weight loss/comorbidities.
Tcholesterol: total cholesterol.
TG: triglycerides.
HDL: high-density lipoprotein.
LDL: low-density lipoprotein.
RYGB: Roux-en-Y gastric bypass.